Redeye provides an initial comment on the Q2 2024 report from Kancera, which showed lower operating ...
CirChem (”CirChem” eller ”Bolaget”) har nyligen stängt böckerna för Q2-24, ett kvartal präglat av fo...
Redeye provides a research update following the Q2 report recently published by Coegin Pharma.
Redeye’s long-term view of Dignitana is, to a degree, intact, even if the sales progression has been...
Gapwaves carried over its momentum from Q1 into the Q2 report, beating Redeye's estimates and consen...
Redeye leaves a research update following Klaria Pharma’s recently published Q2 2024 report.
Sales +4%, adj. EBITA -4% vs. cons, +5% org. sales Cons to lower '24e adj.
Redeye updates on Northbaze following its Q2 results, which were stronger than expected in both sale...
Redeye comments on Active Biotech's Q2 report. New results with naptumomab + docetaxel were presente...
Redeye provides an update following SenzaGen’s Q2 2024 report.
26% organic sales growth y-o-y Growth initiatives hurt profitability mid-term Pricing to act as a ta...
2024e-'26e EBIT raised by 5% We are above the upper end of guidance Strong order book and robust out...
Nettoomsättningen för det andra kvartalet uppgick till 10,2 MEURO (9,5), vilket motsvarade en ökning...
Redeye comments on Nekkar’s H1’24 report that posted mixed results, with continued revenue growth in...
Interimsdata ger ytterligare stöd Interimsdata som presenterades sent under kvartalet från bolagets ...
